Healio Strategic Solutions and the DHC Group released topline data from the first wave of a planned longitudinal look at HCP channel preferences coupled with a survey of pharma marketers. In front of a live audience at Pfizer headquarters in NYC, Mark Bard (Co-Founder, The DHC Group) and Adrienne Stevens Ed.D, (VP, Head of Scientific Strategy, Healio) discussed the implications derived from phase one of the research. The goal of the project was to create a survey model that could be used annually to continuously evaluate the learning behaviors and needs of HCPs and advise pharma companies on the best tactics for reaching HCPs and providing solutions to their pain points.